Full Report

Know the Business

CooperCompanies is two businesses glued together by a disciplined capital allocator. The larger one — CooperVision — is a genuinely advantaged contact-lens oligopolist with a consumable revenue model and pricing power through prescribing eye-care professionals. The smaller one — CooperSurgical — is a roll-up in IVF and women's health whose economics hinge on one irreplaceable product (Paragard) and a long integration runway. The market is underpricing the durability of the lens franchise and overpricing the idea that CSI can grow like a pure-play fertility leader.

1. How This Business Actually Works

CooperVision is a subscription business disguised as a medical device. A fitted contact-lens prescription becomes a recurring SKU that gets re-bought every day (MyDay, Clariti 1-day), two weeks, or month for years. Four players — Acuvue (J&J), Alcon, CooperVision, Bausch+Lomb — control almost the entire $10B+ global market. Switching costs are real: the patient's eye is fit to a specific lens curvature and material, and the eye-care professional writes the Rx. That combination produces price/mix of roughly 2–3 points per year without volume loss.

The incremental dollar of CVI profit comes from trade-up, not new wearers. Volume growth in contact lenses tracks population plus low-single-digit penetration. The real margin engine is category mix: moving wearers from monthly hydrogels into daily silicone hydrogels into specialty (torics/multifocals/myopia management). Dailies are 4–6x the annual revenue of a monthly at similar margins; torics add another layer because astigmatism is growing and harder to copy. Myopia management (MiSight, the only FDA-approved lens slowing childhood myopia progression) is the real optionality — a narrow clinical indication that could convert into a recurring pediatric category.

The bottleneck is manufacturing, not demand. Single-use dailies require enormous cast-molding capacity, and CVI has spent a decade building it — capex has run $300–420M annually, around 9% of sales, well above medtech peers at 3–5%. That capex is both the moat (capacity is a multi-year head start) and the tax on reported FCF. Free cash flow conversion runs close to 55% of EBITDA — respectable, not spectacular.

CooperSurgical is a different animal. It's an acquired collection of IVF consumables, surgical instruments, genomics, and one oversized asset — Paragard, the only hormone-free IUD in the US (~17% share, very high contribution margin). Paragard is both the crown jewel and the single point of failure: any FDA approval of a generic hormone-free IUD would reprice the franchise. The fertility portfolio has genuine scale across the IVF cycle (media, incubators, cryostorage, genomics) but competes with Vitrolife, Merck KGaA's portfolio, and Hamilton Thorne — an oligopoly, but a messier one than contact lenses.

2. The Playing Field

Cooper sits between the true compounders (Edwards, Hologic) and the distressed (Bausch+Lomb), with Alcon as the direct scale analog. The peer set shows what "good" looks like in medical devices — and it's not just gross margin.

Three things this reveals. First, Cooper's GAAP margin is artificially low — amortization of acquired intangibles knocks roughly seven points off reported operating margin. Non-GAAP OM near 25% is the real economic margin, which lines up with Alcon and sits about six points below Hologic. Second, the ROIC gap to Edwards and Hologic is structural, not a choice. Those businesses have narrower franchises (TAVR, breast diagnostics) that reinvest less at higher returns; Cooper has been a buyer of goodwill. Third, Bausch+Lomb shows what the losing end of this industry looks like — same gross margin as Cooper, one-tenth the operating margin, consistent losses. Eyecare is a good business, but only at scale and with manufacturing discipline.

The peer Cooper should be measured against is Alcon. Same revenue mix logic (vision care plus surgical), same capex intensity, same customer channel. Alcon trades richer on EV/EBITDA because its surgical business (IOLs, phaco equipment) has higher pricing power than contact lenses — and because investors still reward its 2019 spin-off transformation story.

3. Is This Business Cyclical?

Short answer: modestly cyclical around elective procedures and premium trade-up; dramatically cyclical around M&A integration. The consumable lens base is recession-resistant — people still wore glasses and contacts in 2009 and 2020 — but margins get hit by two levers: trade-up pauses (consumers defer premium dailies for cheaper monthlies) and FX (about 55% of revenue is non-US).

The two real stress tests tell different stories. The 2005–2008 Ocular Sciences integration (doubled revenue, crushed margin to 5.8%) was self-inflicted and took three years to repair — it's a warning about aggressive M&A, not a cycle signal. COVID 2020 is the cleaner cycle read: revenue dropped 8%, operating margin fell about 700bp, elective eye exams paused, IUD insertions were deferred, fertility cycles postponed. Both lines fully recovered within four to six quarters. The resilience read-through: roughly 65–70% of revenue (core contact-lens base) barely moved; all the volatility was in the elective and premium tail.

Where the cycle actually hits: (1) Fertility cycle volume — IVF is heavily out-of-pocket, so consumer-confidence sensitive, especially in China/APAC (Q1 FY26 Asia-Pacific down 4%; fertility in China weak, partly attributed to the Year of the Snake demographic pattern). (2) Premium lens trade-up — slower mix-up in recessions is a margin story, not a volume story. (3) FX — a strong dollar cuts reported growth by 3–5 points in some years. (4) Rate cycles flow through roughly $2.5B of long-term debt (interest expense jumped from $23M in FY21 to $114M in FY24).

4. The Metrics That Actually Matter

Stop looking at GAAP EPS. Cooper's economic engine shows up in five numbers — and most of them are not in the headline tables.

CVI organic growth is the single number that drives the stock. When it was 7–9% (FY2022–FY2024), Cooper traded at 25–30x forward non-GAAP EPS and sell-side models assumed a long runway. FY25 and guided FY26 organic growth of 4.5–5.5% is the critical inflection — if 5% is the new steady state, this is a 15–20x business, not a 25x business. Q1 FY26 came in at 3% organic on tough comps with currency help; the next three quarters decide the multiple.

Paragard is the hidden concentration. Back-of-the-envelope, Paragard is roughly $200M of revenue at a very high incremental margin, so it punches well above its revenue weight on EBITDA. It's the only hormone-free IUD in the US. A generic approval would not just compete on price — it would remove a structural gross margin contributor in CSI. Monitor the FDA approval pipeline for pending hormone-free IUD applications.

Non-GAAP operating margin is the real P&L. GAAP operating margin of 16.7% in FY25 is suppressed by $377M of amortization on acquired intangibles — a non-cash charge that will decline mechanically over the next decade. Non-GAAP OM of roughly 25% is both historically stable and the number guidance is given in. Decomposing: contact lens margin is high-20s, surgical mid-20s, corporate drag of ~2 points.

5. What I'd Tell a Young Analyst

Don't confuse the lens business with the roll-up. CooperVision is a genuine oligopoly with pricing power, capacity moats, and a multi-decade trade-up runway into dailies and myopia management. Value it like Alcon's vision segment. CooperSurgical is execution-dependent — the IVF integration has been competent but unspectacular, and Paragard is one FDA decision away from a reset. Don't pay the same multiple for both.

The GAAP-vs-non-GAAP gap is real. $377M of amortization drops off over roughly a decade; that's a mechanical EPS tailwind that doesn't require operational execution. Analysts who anchor on reported net income and miss this will conclude Cooper is a 30x stock when it's closer to a 15x stock on cash earnings.

What would genuinely change the thesis — either way. Bull case flips in motion: MyDay MiSight ramps internationally (turning myopia management from a $100M niche into a $500M+ category) and silicone hydrogel daily capacity comes fully online and lifts margin 200bp. Bear case flips: a second FDA-approved hormone-free IUD enters the US; e-commerce private-label dailies (already about one-third of CVI revenue) pressure branded pricing; CVI organic growth settles at 3% instead of 5%.

What the market is most likely misreading right now. The stock is down 22% over 12 months on what the market is treating as a structural slowdown. The data suggest something milder: tough comps, China weakness, tariff drag on gross margin, and a reorg that temporarily muddies the P&L. If organic growth stabilizes at 5% and non-GAAP OM expands to 27%+ as guided, this is a mid-cycle buy. If organic growth breaks below 4% while BLCO-style e-commerce pricing pressure shows up, the re-rating isn't done. The FY26 quarters are the call.

The Numbers

Cooper is a 30-year compounder — contact lenses plus women's-health devices — that the market is currently treating like a broken growth story. The stock fell from $105 (October 2024) to $65 (April 2026), yet the underlying Quality Score is 90/100, the Fair Value estimate sits near $103, and the newest quarter delivered the strongest operating margin in four years. The single metric most likely to rerate or derate the stock from here is CooperVision growth — the 67%-of-revenue contact-lens franchise whose deceleration explains most of the derating since late 2024.

Snapshot

Is this a well-run business that will still be around in ten years?

The quality signals agree: this is a durable, predictable business with a reliably profitable core. The one caveat is the middling Piotroski — it's dinged because growth is prioritized over book-value accretion, which is the correct trade for a roll-up that keeps buying growth in fertility and specialty vision care.

Revenue & earnings power — 30-year view

Revenue compounded at a 14.6% 30-year CAGR. Operating margin averaged roughly 17% through the last decade with two clear drawdowns: FY2015 (Sauflon integration) and FY2020 (COVID elective-procedure stall). The FY2021 net margin of 101% is a one-time $2.4B tax benefit from an IP restructuring — it's excluded from the margin chart so the underlying trend reads cleanly. Net margin is structurally lower than operating margin because interest expense and amortization of intangibles from roll-up M&A take a big bite every year.

Recent quarterly trajectory — why the stock was punished

Revenue grew quarter-over-quarter through most of FY2024–25, but operating margin collapsed from 19.5% in 4Q24 to 13.2% in 4Q25 on inventory build and FX pressure — the proximate trigger for the 38% price drawdown. Then 1Q26 snapped back to 20.8% operating margin, the highest in four years, with earnings of $0.66 per share. If the market has this right, 1Q26 was the trough reversal; if wrong, 4Q25 was a warning about sustainable profitability.

Segment mix — what actually drives the model

CooperVision contributes 67% of revenue and the vast majority of operating profit; CooperSurgical is 33% and anchored by the Paragard IUD and a fertility platform built through acquisition. CooperVision grew 5.2% in FY2025, decelerating from 7.7% in FY2024 — that single data point is most of the reason the stock is where it is. CooperSurgical delivered steadier 4.9% growth.

Cash generation — are the earnings real?

Operating cash flow has run well above reported net income every year since 2017 — the ~$375M gap in FY2025 is non-cash amortization of intangibles left over from the Paragard and Generate Life Sciences deals. Strip out FY2021's one-time tax benefit and four-year (FY2022–25) FCF-to-NI conversion is 96%. The earnings are real. The story investors should see: elevated capex in FY2023–24 (new contact-lens manufacturing capacity in Costa Rica and Puerto Rico) has peaked; FCF rebounded to $434M in FY2025 and should keep rising as capex normalizes back toward 6–7% of revenue.

Capital allocation — an M&A machine that's slowing down

Cooper is historically an M&A roll-up: three transformational deals dominate the last decade — LifeGlobal fertility in FY2018 ($1.3B), Generate Life Sciences in FY2022 ($1.6B), and smaller bolt-ons between. FY2025 marks a pivot: dividends were eliminated (FY2024), acquisitions collapsed to $11M, and the company began repurchasing stock meaningfully for the first time ($290M). Stock-based compensation is well-behaved at ~$70M / 1.7% of revenue. The shift from "acquire to compound" to "repurchase at trough" is a high-return capital-allocation pivot if the 1Q26 margin rebound is durable.

Balance sheet — post-roll-up but not stretched

Leverage peaked at 3.5x Net Debt/EBITDA after the FY2018 LifeGlobal deal and 3.1x after Generate Life Sciences in FY2022. The company has deleveraged steadily; current Net Debt/EBITDA of 2.3x is below the 10-year average and comfortable for a recurring-revenue medical-device business. Altman Z-Score of 3.44 sits in the safe zone, and interest coverage of 6.8x handles the $100M annual interest bill comfortably. No refinancing risk; the balance sheet is not the story here.

Valuation — now vs its own 20-year history (the critical chart)

This is the most load-bearing chart on the page. Cooper trades at 13.8x EV/EBITDA today — roughly 1.3 standard deviations below the 5-year mean of 20.5x and 0.8 standard deviations below the 20-year mean of 17.8x. It is the cheapest the stock has been since 2013 outside of the 2008 panic. Every other marker agrees: P/B at 1.66x vs the 10-year average near 3.0x; P/FCF at 32x vs the 5-year mean closer to 50x. The market has repriced Cooper from "premium medical-device compounder" to "mid-single-digit grower" — the question for the investor is whether that repricing is correct.

Per-share economics

Share count has stayed near 200M for a decade — dilution is a non-issue. Revenue per share doubled from $10 to $20 over ten years. EPS has been lumpier because of M&A amortization, but FCF-per-share has also doubled. The $290M FY2025 buyback should begin to compound per-share metrics meaningfully if repeated.

Peer comparison

Cooper trades at the cheapest EV/EBITDA in the cohort — 13.8x vs Alcon and Edwards both around 31x and Hologic at 16x. The easy pushback is that Edwards earns a 50% ROIC and deserves the premium; Alcon is more diversified. But Cooper's 23% ROIC and 17% operating margin put it squarely in the middle of the group on profitability, not at the bottom — yet it trades with the only unprofitable name (Bausch & Lomb) on multiple. The gap is either opportunity or warning; the next two quarters of CooperVision growth will decide.

Fair Value & scenarios

The bottom line

The numbers confirm Cooper is a financially healthy, cash-generative business with a strong competitive position: 23% ROIC, 90/100 Quality Score, declining leverage, and real earnings (FCF-to-NI tracks ~96% over four years). They contradict the popular narrative that the business is structurally impaired — 1Q26 delivered the best operating margin in four years, capex is past its peak, and management has pivoted to shareholder-friendly buybacks for the first time. Watch CooperVision growth in the next two quarters: the stock re-rates only if that franchise reaccelerates past 6% organic; if growth stalls below 4%, the current 14x multiple may become the new normal regardless of the 58% spread to model Fair Value.

Management & Governance

Grade: C+. CooperCompanies has functional governance on paper — separate Chair and CEO, 100% independent board, clawback, anti-hedging — but two activist campaigns in late 2025 forced an admission that the watchdogs were asleep on capital allocation. A cooperation agreement in December 2025 placed a Browning West-backed director on the board and put the Chair role in play. Incentives rewarded revenue growth without regard for ROIC or free cash flow, and insiders (most notably 30-year director Bob Weiss) sold over $100M of stock since 2019 while returns on capital deteriorated. The refresh is real but incomplete.

The People Running This Company

Five Named Executive Officers. The CEO came up through finance and ran CooperSurgical before the top job — which is exactly the unit activists argue has been starved for discipline. The rest of the team is functional but not glamorous: a career-insider CFO, a lawyer-turned-COO, and two divisional presidents recruited from banking and a competitor.

What matters for trust: Al White's background is the one to scrutinize. He was CEO of CooperSurgical (2015–2018) immediately before becoming corporate CEO — the exact unit activists say has destroyed capital with a cumulative ROIC below 5% on $4B of investment. Jana's public note puts it bluntly: the parent-company CEO is the person least equipped to critically re-underwrite CooperSurgical. Sheffield inherits the same scrutiny, having run CooperSurgical through the period the company now admits "is not as efficient as it should be."

Succession: There is no publicly named heir apparent. McBride has the breadth to serve as caretaker; Andrews has only been CFO five years. If the activists succeed in separating the businesses, Warner is the natural continuing CEO of a pure-play CooperVision.

What They Get Paid

CEO pay of $16.0M for FY2025 is in line with peer medical-device CEOs, but the pay-ratio and pay-versus-performance tension is unusually sharp for a company whose stock fell more than 30% over the measurement window.

Structure and issues:

• Roughly 93% of White's target comp and 83% for other NEOs is "performance-based," but until fiscal 2026 the three-year PSU metric was adjusted constant-currency EPS growth only. Revenue, EPS, and FCF drive the annual IPP. Neither ROIC nor TSR were incentive inputs.
• The FY23–FY25 PSU cycle paid out at the 200% maximum (on 11.1% EPS CAGR versus an 11% cap) — a result Browning West attacks as "growth at all costs," since EPS growth was partly delivered via acquisitions while FCF declined from $421M (2019) to $288M (2024).
• After the activist letters the OCC added a 25% weighting of three-year relative TSR to FY2026 long-term grants, benchmarked against the S&P 500 Healthcare Equipment Index. This is a direct response to the criticism and is the single most substantive governance concession.
• Pay-versus-performance math is stark: FY25 "Compensation Actually Paid" to the CEO was $1.77M versus $16.05M reported, because a collapsing stock mechanically revalued his unvested equity downward. Alignment with stockholders on the way down is working; alignment with value creation clearly was not.

Are They Aligned?

Ownership

Insider ownership is small — 2.08% for all directors and officers combined. There is no founder or promoter stake. The shareholder register is institution-dominated.

Insider buying vs selling

The most striking signal is that in the second half of calendar 2025, every insider on record was a buyer, not a seller. Ten open-market purchases totalled about $2.5M at prices from $65 to $84. The CEO personally bought 20,000 shares at an average cost of $74. Zero open-market sells appear in the last twelve months of Form 4 filings.

The Weiss problem

Bob Weiss has been a director for 30 years. He was CEO from 2007 to 2018 and Chairman until the 2025 activist campaigns. He remains on the board and the proxy still labels him independent. That label is a stretch. Weiss has sold over $100M of Cooper stock since 2019 — including $29M in December 2023 at $91.20 and another $12.7M in March 2023 at $84.43. He still owns 546,805 shares (about $35M at current prices), of which 257,860 are held in an estate planning trust.

Browning West's letter singled Weiss out directly: "Mr. Weiss has sold over $100 million of Cooper stock since 2019" while "presiding over several years of value destruction." The company has since named Colleen Jay incoming Chair and committed to seriously consider Rosebrough for Chair by end of 2026 — effectively a planned exit path for Weiss from the Chair role, though he remains a 2026 director nominee.

Dilution and capital allocation

FY2025 was share-friendly at the margin: Cooper repurchased $290M / 4.1M shares at an average $69.30. Over a longer frame the picture is worse. Browning West calculates roughly $4B deployed into CooperSurgical at a cumulative ROIC below 5%, and says the company could not articulate to them the ROIC on $1.7B of CooperVision capex from 2019 to 2024. No explicit ROIC gate in incentives means capital discipline was a soft constraint at best.

Related-party transactions

None disclosed for FY2025. The policy requires Audit Committee pre-approval, KPMG reviews controls, and the proxy specifically states "we have determined that there were no related party transactions requiring disclosure." This is a legitimate green flag.

Skin-in-the-game score

Why 4.5/10: the CEO holds roughly $16M in stock (plus 1.7M exercisable options); all insiders combined own 2.08%. Recent insider buying is a positive signal (worth about one point). Offsetting: no founder or promoter with a concentrated long-term stake, historical pattern of aggressive selling by the former CEO/Chairman, and until FY2026 incentive metrics did not require ROIC or TSR hurdles. The refreshed FY2026 plan adds TSR, worth another half point once performance-tested. If the board adds an ROIC gate, this score moves to 6.

Board Quality

Post-refresh, Cooper's board is nine directors — eight independent plus White as the only insider. Excluding Weiss, average independent tenure is about four years.

What the board is good at: finance and audit oversight (three former CFOs plus a former KPMG audit partner), separate Chair and CEO, no poison pill, majority voting standard, proxy access, annual self-evaluation with a third-party administrator, and committee independence.

What it's demonstrably not good at: operating expertise in the businesses Cooper actually runs. Until Rosebrough joined in January 2026, zero directors had operating experience in vision care or were medical-device CEOs with a track record of value creation. The CEO Al White himself serves on only one outside board (Evolus). Board members' secondary directorships skew consumer (Jay at Beyond Meat, Kurzius at Lamb Weston) rather than medical devices.

The Verdict

Strongest positives:

• Procedural hygiene is strong: independent Chair, fully independent committees, no poison pill, clawback, anti-hedging, double-trigger change-in-control, no tax gross-ups, no related-party transactions disclosed.
• Insiders put their own money down in 2H 2025. Eight buyers, zero open-market sellers in the most recent twelve months of Form 4s.
• The activist settlement produced a genuinely high-quality addition (Rosebrough delivered an 18% CAGR over fourteen years at STERIS) and, for FY2026, a new 25% relative-TSR PSU component that directly addresses one of the loudest criticisms.

Real concerns:

• The fact that two activists had to show up in the same quarter to get these changes is itself the verdict on board oversight. Browning West's claim is not that Cooper's governance policies are weak; it's that the board applied them to a strategy — growth at any cost in CooperSurgical — that was destroying capital and rewarded management for it.
• Weiss's 30-year tenure and documented selling pattern undermine the independence claim on paper. He remains a 2026 nominee.
• Until FY2026, incentive plans had no ROIC gate and no TSR test. The board approved a 200% PSU payout for the FY23–FY25 cycle during a period in which the stock underperformed its sector by more than 100 percentage points over five years.
• The CEO is the former head of the division activists want broken off. Any strategic review of CooperSurgical is awkward for him to lead credibly.

The one thing that moves the grade:

• Upgrade to B+ if Rosebrough is named Chair, Weiss retires by the 2027 annual meeting, an ROIC hurdle is added to incentive metrics, and the board publicly re-underwrites CooperSurgical's capital allocation.
• Downgrade to C if the cooperation agreement is the ceiling — Rosebrough is a single seat, Weiss stays on, and the FY2026 TSR metric is the only substantive comp reform.

The Full Story

Between FY2021 and today, Cooper has walked three very different corporate narratives: a COVID rebound built on silicone-hydrogel volume, a debt-funded acquisition spree centred on Generate Life Sciences and Cook Medical, and — since mid-FY2025 — a cost-out, cash-return, "eight consecutive earnings beats" story stitched together after two back-to-back organic guide cuts. Revenue growth has re-rated from 6–8% to 4–5%, the 13-quarter fertility double-digit streak was quietly retired in Q2 FY24, and two activists (Jana Partners, Browning West) are now pushing for a break-up of CooperVision and CooperSurgical. Management has defended every EPS line but conceded ground on every growth line — the current story is simpler, less stretched, and demonstrably less ambitious than the one pitched two years ago.

1. The Narrative Arc

The growth profile tells the story in one chart: FY21's 20% was a pandemic-rebound anomaly, FY22–FY24 settled into an 8–10% corridor that framed every earnings call, and FY25 collapsed to +4% — the structurally lower level management is now guiding (4.5–5.5% for FY26). The re-rating from "high single / low double-digit grower" to "mid-single-digit grower" is the single most important fact of the last five years.

2. What Management Emphasized — and Then Stopped Emphasizing

Five patterns jump off the heatmap. (1) The double-digit organic boast — the signature line through Q1 FY24 — disappears after the fertility streak breaks. (2) Fertility streak framing was cited 13 straight quarters, then never cited again. (3) Margin, FCF, buybacks, and reorganization — the current "Cooper 2.0" narrative — all ramp simultaneously starting Q3 FY25, exactly as organic growth rolls over. (4) MyDay has been the one constant, moving from supporting player to lead; MiSight becomes a top-emphasis story only in Q4 FY25 (+37% in the quarter). (5) Capacity expansion — drumbeat for eight quarters — goes quiet once "completing" is reached in Q2 FY25, replaced by cost-out language.

3. Risk Evolution

What became more important. Tariffs graduated to a standalone risk header in FY24 and now rank among the top three in FY25, reinforced by explicit GM-drag language in Q4 FY25 and Q1 FY26 ("excluding the impact of tariffs, gross margin would have been flat"). Cybersecurity evolved from a generic paragraph in FY21 to a detailed disclosure including a dedicated team with CISSP/GIAC credentials (FY22), and then to a Section 524B FDCA medical-device cybersecurity framework (FY25) with formal SBOM obligations. EU MDR/IVDR compliance and the FDA LDT Final Rule peaked as risks in FY24; the LDT rule was vacated in March 2025 and rescinded in September 2025, softening that exposure.

What became less important. COVID-19 collapsed from the lead risk in FY21 to absorbed boilerplate by FY24. Brexit went from a dedicated section in FY21 to a single line by FY24. The Russia-Ukraine war header — introduced as a new standalone risk in FY22 — was folded back into generic "international conflicts" language in FY25.

What appeared fresh. The FY24 disclosure of a material weakness in IT general controls at CooperSurgical's US operations (tied to the ERP implementation that also broke the fertility double-digit streak in Q2 FY24) was a genuine red flag — remediated by end of FY25 but a reminder that the acquisition machine outran its integration controls. The FY25 workforce-optimization and severance language is new and directly tied to the $89M reorganization charge.

Paragard watch. Through five years, product-liability litigation has never been elevated to a named Risk Factor — it sits inside the generic "product liability claims" paragraph. The only escalation: FY24 and FY25 explicitly name "Paragard IUDs" inside direct-to-consumer marketing risk language, a subtle acknowledgment that plaintiff activity warrants a nameplate, but well short of specific claim counts or reserves.

4. How They Handled Bad News

Three episodes define the credibility stress test.

Episode 1 — Q2 FY24: the fertility streak breaks. CooperSurgical's 13-quarter double-digit fertility organic streak snapped to +4%, and management attributed it, almost in passing, to a distribution-center system upgrade.

"CooperVision returned to double-digit growth… unexpected challenges with a system upgrade in our US distribution center." — Q2 FY24, May 2024

This mattered because fertility was the signature growth anchor, and the explanation was narrow (one data centre) for a reversal that, as the heatmap shows, never recovered to sustained double digits. Framing it as a one-line operational hiccup rather than a demand inflection was optimistic and — in hindsight — premature.

Episode 2 — Q3 FY25: "revenues below expectations." Two quarters after cutting the FY25 organic range from 6–8% to 5–6%, management cut it again to 4–4.5% and pivoted explicitly to a forward story.

"Our revenues were below expectations but we're raising earnings guidance… expect improving revenue in Q4 and in fiscal 2026 driven by MyDay." — Q3 FY25, August 2025

This quote captures the trade management has been running ever since: honest on EPS, aspirational on revenue re-acceleration. CVI sphere turned negative organic for the first time in the window. The stock fell roughly 13% the next session and triggered both the $89M reorganization and the activist campaigns that followed.

Episode 3 — Q4 FY25 / Q1 FY26: the reframe. Management replaced the growth-streak narrative with an earnings-consistency narrative.

"Closed FY25 ahead of consensus revenue, earnings, and free cash flow expectations… eight consecutive quarters of earnings beats." — Q4 FY25, December 2025

The reframe is executed cleanly: $89M of charges producing $50M/year of annualized savings, a $1B buyback expansion at depressed prices, a 3-year cumulative FCF target above $2.2B, and a 180 bps non-GAAP op-margin expansion already visible in Q1 FY26. Credible and tangible — but also a structural admission that the old growth rate is gone.

5. Guidance Track Record

FY23 and FY24 guides were beaten; FY25 is the break. The initial FY25 organic guide of 6–8% (midpoint 7%) landed at +4% — roughly 300 bps below the midpoint and 200 bps below the low end. EPS beat every year, including FY25 ($4.13 vs $3.92–4.02 guide).

Two successive cuts within one fiscal year — a signature of a growth story in transition, not an execution hiccup.

6. What the Story Is Now

Cooper today is a mid-single-digit organic grower with expanding margins, returning cash, and an open strategic review — a fundamentally different pitch from the "high-single / low-double-digit grower with a fertility growth engine and a silicone-hydrogel flywheel" that framed FY22–FY24. Three things have been genuinely de-risked: balance sheet (net debt down, interest expense down 13% YoY, $2.3B revolver refinanced), earnings power (eight-quarter EPS beat streak, 180 bps op-margin expansion in Q1 FY26, $50M/yr of reorganization savings flowing), and capital return (buyback authorization expanded to $2.0B, 4.1M shares repurchased in FY25, Al White's personal $808K insider buy in December 2025). Three things still look stretched: the MyDay / MyDay Energys / MiSight acceleration story has been promised forward for multiple quarters and now needs to actually show up in CVI organic; tariffs are a persistent, widening GM drag that management has not solved; and the activist push from Jana Partners and Browning West — centred on separating CooperVision from CooperSurgical and on CooperSurgical's sub-par returns on more than $3B of capital deployed since 2017 — is a live governance risk that could drive a structural outcome management has not steered into.

Believe: the cost discipline, the FCF target, and the EPS floor. Discount: the "re-acceleration in FY26 driven by MyDay" line until at least two consecutive quarters of CVI organic back above +5%, and any claim that CooperSurgical can earn adequate returns on the fertility build-out without a structural change. The current story is simpler and more honest than the one pitched two years ago — which is itself an admission that the earlier story was more stretched than management disclosed at the time.

What's Next

The next three to six months are unusually catalyst-dense for a mid-cap medtech. The next earnings print lands in late May / early June 2026, inside an active Browning West cooperation window and with a strategic review of CooperSurgical underway. Q2 FY26 carries outsized weight because it is the first opportunity for CooperVision organic growth to print above 5% since the Q1 FY26 low of ~3% — the single number on which this entire debate turns.

The EPS line has beaten consensus for nine consecutive quarters — that is the management narrative. The revenue line has missed and been cut three times inside FY25 — that is the bear narrative. Q2 FY26 is where the two lines collide: a tenth EPS beat no longer moves the stock if CVI organic stays under 5%. The market is watching the organic print, not the EPS number.

For / Against / My View

The setup is a quality oligopoly at a thirteen-year low multiple, activists pressing for break-up, and a management team that has defended every EPS line but conceded ground on every growth line. Below are the three sharpest arguments on each side — lifted largely from Bull and Bear's drafts — followed by where they disagree on the same fact.

For

Bull price target: $102 (+57%) over 12–18 months — EV/EBITDA reversion to the 20-year mean of ~17.8x on FY26 EBITDA ~$1.15B, cross-checked against Fair Value of $102.70 and Medpsvalue estimate of $109.45. Primary catalyst: CooperSurgical strategic review outcome combined with one more CVI organic print above 5%.

Against

Bear downside target: $52 (-20%) over 12 months — FY26 non-GAAP EPS haircut to $4.30 × 12x multiple (cohort floor for mid-single-digit medtech compounders); EV/EBITDA 11x on ~$1.0B FY26 EBITDA cross-checks at ~$50. Primary trigger: a fourth consecutive CVI organic print under 5%, or a CSI sale at or below book value.

The Tensions

1. CVI organic growth: trough or new normal?

Bull says the CooperVision deceleration from 8% → 5% → 3% is a combination of tough FY24 comps, FX, China tariffs, and a reorg-induced P&L muddle — transitory, with MyDay and MiSight set to re-accelerate. Bear says the same sequence is structural — CooperVision is now a 3–5% compounder, and the guide being cut three times in a row is confirmation, not aberration. Both cite the same 8% / 5% / 3% walk. This resolves on two consecutive CVI organic prints above 5% — the first opportunity is Q2 FY26 (late May / early June 2026), the second is Q3 FY26 (late August 2026). Anything under 5% for a fourth straight quarter tips the tension to the Bear.

2. The activist pivot: unlock or capitulation?

Bull reads the Browning West stake, new chair, $2B buyback, $2.2B FCF target, and eight insider buys as the textbook setup where an activist forces a re-rating at the low. Bear reads the exact same sequence as a board capitulating under duress, abandoning the M&A growth model it defended two years ago, and entertaining a CooperSurgical divestiture at cycle-trough fertility multiples. Both cite the same events in Oct–Dec 2025. This resolves on the CooperSurgical strategic review outcome — a clean CSI separation at an accretive multiple with the buyback sustained is Bull's outcome; a CSI sale at or below book, or a "status quo" announcement that preserves the structure the activists targeted, is Bear's.

3. The $2.2B three-year FCF target: credible ramp or arithmetic fiction?

Bull says FY25's $434M of FCF already doubled FY23's $215M; capex peaked in FY23-24 and is normalizing toward 6–7% of sales, which alone gets most of the way to the $730M/yr pace. Bear says hitting $730M from $434M is a 70% step-up that collides with halved CVI growth, 60–70bp of tariff gross-margin drag, and capex still at 9% of sales. Both cite the same FY25 $434M starting point and the same $730M implied annual pace. This resolves on H1 FY26 FCF run-rate — the Q2 FY26 cash-flow statement (late May / early June) will show whether the business is tracking ~$350M or ~$200M through the first half. Under $300M at the half-way mark and the target becomes narrative, not arithmetic.

My View

Close call, slight lean cautious. The valuation is real — 13.8x on a 90-Quality business with a 23% ROIC, clean Beneish, and a 4.1-star predictability is genuinely rare, and the insider-buy cluster is the kind of signal that usually marks a low. But the first tension is doing most of the work: a stock multiple for a contact-lens oligopoly rests almost entirely on CVI organic growth, and three prints of a deceleration — culminating in a 3% handle last quarter — is not yet a trough; it is a line. I would wait for the Q2 FY26 print in late May / early June 2026 before stepping in, rather than pay for mean reversion that still depends on a number that is going the wrong way. The single condition that would flip this view: CooperVision organic growth prints above 5% in Q2 FY26 — on that one number the first tension collapses toward the Bull, the margin reset gets a revenue denominator behind it, and the 20-year-mean multiple argument goes from plausible to likely.

Web Research

The Bottom Line from the Web

The filings describe a steady-state medical-device company. The internet describes a company under siege. Between late October 2025 and December 2025, two activist funds — Jana Partners and Browning West (with over $500M invested) — launched parallel campaigns demanding a break-up of Cooper Companies, a merger of CooperVision with Bausch + Lomb, a board overhaul, and a strategic review of CooperSurgical. On December 4, 2025, the company capitulated: it announced a formal strategic review and a new board chair, sending the stock up roughly 12% after hours. As of April 2026, the activist story is the dominant driver of the stock — not contact-lens organic growth, not fertility-market dynamics, not FX. Anyone valuing COO off historical earnings power without pricing in a potential break-up is working with a stale thesis.

What Matters Most

1. Dual activist campaigns demanding a break-up

2. Company caved: strategic review launched, new board chair named

3. Q4 2025 was a disaster on earnings even as revenue held

4. Stock has materially underperformed — down 22% over one year

5. CFO also took principal accounting officer role on Dec 9, 2025

6. Board authorized a $1 billion buyback increase in September 2025

7. Analyst consensus is intact but dispersion is wide

8. Shareholders backed incumbent management at the annual meeting

9. Historical governance episodes worth naming

10. CEO Al White owns 0.13% of company ($18M) — modest for an 8-year tenure

White has been CEO since May 2018 (previously CFO). Simply Wall St reports FY2024 total comp at ~$16M (~7.3% salary, 92.7% performance/equity). Stock ownership of ~0.13% ($18M) is directionally aligned but not large relative to tenure, and EPS growth over the trailing three years has been materially negative per prior analyses. White also joined Evolus (EOLS) as an independent director in July 2024 — a side gig that is not unusual but adds attention drain during an activist campaign. Source: simplywall.st management page; finance.yahoo.com Simply Wall St compensation analysis 2024-03-13.

Recent News Timeline

What the Specialists Asked

Insider Spotlight

Albert G. White III — CEO and President

Appointed May 2018 (previously CFO 2016–2018; CEO of Cooper Medical 2015–2018). FY2024 total comp ~$16.05M with 7.3% base salary — a pay structure heavily tilted to equity and bonus, which is standard for a medium-to-large cap medical device company. Direct stock ownership ~0.13% ($18M at current prices). Added independent directorship at Evolus Inc. in July 2024. Prior Simply Wall St analysis noted CEO compensation was "in line with the median for the industry" but flagged that EPS fell ~50% over the three-year window ending FY2023 — a disconnect between pay and EPS outcomes that shareholder advisory firms typically scrutinize. Shareholder advisory vote on pay passed at the most recent AGM.

Brian G. Andrews — CFO, Treasurer, and now Principal Accounting Officer

CFO/Treasurer since 2018, EVP since 2020. On December 9, 2025 he took on principal accounting officer duties from Agostino Ricupati (who remains SVP Tax). Consolidating PAO inside the CFO during an active strategic review is atypical enough to flag, though not necessarily negative. Andrews has been the public-facing financial voice on all recent earnings calls including the Q4 2025 call that produced the $0.70 EPS miss.

Daniel G. McBride — COO, EVP, President CooperVision

Reported by Comparably as the highest-paid named executive at $3.7M annually. As President of CooperVision he runs the division the activists want to keep and scale. If a break-up occurs, he is the natural internal candidate to lead a CooperVision-standalone entity.

Holly Sheffield — EVP and Chief Strategy Officer

Appointed June 2018 (announced alongside White's CEO elevation). Role covers corporate strategy and business development — i.e., the exact function that would be leading any strategic review or divestiture process today.

Industry Context

The global medical-device market is estimated at $572–679B in 2025, projected to reach $1.03–1.21T by 2034–2035, implying a ~5–6% CAGR. Cooper operates in two specific sub-segments:

• Contact lenses. Structural tailwinds remain: ~40% of wearers still use non-daily lenses creating a multi-year upgrade runway to silicone-hydrogel dailies; growing global wearer base; high barriers to entry. CNBC's Jana Partners summary puts CooperVision EBITDA margin in the mid-30s. The competitive set (Alcon, J&J, Bausch+Lomb, Hoya) is concentrated enough that a Cooper–Bausch+Lomb combination might actually face less antitrust resistance than it initially appears, because it would create a clearer #2 to Alcon/J&J.

• Fertility/IVF and women's health. Fertility treatment is a ~$2B global market growing 4–6% annually. Cooper has broad IVF-cycle coverage but faces questions about strategic fit within a contact-lens parent. The activist prescription is either cleaning up the portfolio internally (Jana's view) or separating CooperSurgical entirely (Browning West's view).

Near-term headwinds per management commentary: macro pressure on consumer spending, global FX (1.5% revenue / 4% EPS drag in FY25), inventory normalization in fertility, and new competitive entrants in IUD and contact lens segments.